Centrally active and orally bioavailable antidotes for organophosphate exposure and methods for making and using them
US-2015361060-A1 · Dec 17, 2015 · US
Crystalline forms of an 8-azabicyclo[3.2.1]octane compound
US9290491B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9290491-B2 |
| Application number | US-201414333003-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 16, 2014 |
| Priority date | Feb 28, 2007 |
| Publication date | Mar 22, 2016 |
| Grant date | Mar 22, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and processes useful for preparing such crystalline salt forms.
First claim
Opening claim text (preview).
What is claimed is: 1. A crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide wherein a single crystal of the sulfate salt, analyzed at a temperature of −153±1° C., is characterized by an orthorhombic unit cell with dimensions a=6.824 Å, b=16.228 Å, c=24.202 Å, α=β=γ=90°; cell volume (V) of 2680.0 Å 3 , and a space group of P2 1 2 1 2 1 (#19). 2. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the crystalline sulfate salt of claim 1 .
Assignees
Inventors
Classifications
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Centrally acting analgesics, e.g. opioids · CPC title
Drugs for disorders of the alimentary tract or the digestive system · CPC title
for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants · CPC title
Morphinan derivatives, e.g. morphine, codeine · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9290491B2 cover?
- The invention provides a crystalline sulfate salt of 3-endo-(8-{2-[cyclohexylmethyl-((S)-2,3-dihydroxy-propionyl)amino]ethyl}-8-aza-bicyclo[3.2.1]oct-3-yl)benzamide or a solvate thereof. The invention also provides pharmaceutical compositions comprising such crystalline salt forms, methods of using such crystalline salt forms to treat diseases associated with mu opioid receptor activity, and pr…
- Who is the assignee on this patent?
- Dalziel Sean M, Preza Leticia M, Rapta Miroslav, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification C07D451/02. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).